Stock Code 603707.SH

• ABOUT

  >
  Company profile Enterprise Culture Early Warning System
• PRODUCTS

  >
  Product List Commercialized Products
• INNOVATION

  >
  Small Molecule Pharmaceuticals Macromolecule pharmaceuticals Global Regulatory Registration Support Commercial cooperation
• MEDIA

  >
  News in NKF Industry dynamics
• CONTACT

CH / EN

Macromolecular pharmaceutical R&D platform

Home  >  INNOVATION > Macromolecule pharmaceuticals

Global Bio-innovative Drug Deployment Strategy

• 2025

  Novel mRNA technology-based biologic drug treatment options
  

• 2030

  Bio-innovative drug combinations
  （mAb和mRNA）Biopharmaceutical Product Launch
  

• 2035

  fully integrated multi-therapeutical area, international company eith multi biotechnology platforms
  

Development of bio-innovative drugs

In the next 15 years, bio-innovative drugs motivate the realization of the whole industry chain capability of large molecule biologics from stock solution to formulation.

Nanjing Headquarter

Drug development and commercialization based on mRNA technology

Cheng Du

Development and manufacturing of monoclonal antibody drugs

Chicago, USA

Global Clinical Research Center
U.S. Marketing

Talk to our researchers about your project

Click to enter

• ABOUT
• INNOVATION
• MEDIA
• CONTACT
• PRODUCTS

Stock price

13.240

-0.06

©2024 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd苏ICP备13012010号

• Disclaimers
• Privacy policy
• Site map

XML 地图